Mirtazapine augmentation in treatment-resistant major depressive disorder: an open-label, six-week trial

被引：0
|
作者：
Aydemir, O [1 ]
Taskin, EO [1 ]
Deveci, A [1 ]
机构：
[1] Celal Bayar Univ Hosp, Manisa, Turkey
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2005年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S401 / S402
页数：2
相关论文
共 50 条
  • [1] An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder
    Menza, Matthew A.
    Dobkin, Roseanne D.
    Marin, Humberto
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2007, 27 (02) : 207 - 210
  • [2] Memantine Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder An Open-Label Trial
    Aboujaoude, Elias
    Barry, John J.
    Gamel, Nona
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2009, 29 (01) : 51 - 55
  • [3] Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial
    Coric, V
    Taskiran, S
    Pittenger, C
    Wasylink, S
    Mathalon, DH
    Valentine, G
    Saksa, J
    Wu, YT
    Gueorguieva, R
    Sanacora, R
    Malison, RT
    Krystal, JH
    BIOLOGICAL PSYCHIATRY, 2005, 58 (05) : 424 - 428
  • [4] Olanzapine augmentation in treatment-resistant panic disorder - A 12-week, fixed-dose, open-label trial
    Sepede, G
    De Berardis, D
    Gambi, F
    Campanella, D
    La Rovere, R
    D'Amico, M
    Cicconetti, A
    Penna, L
    Peca, S
    Carano, A
    Mancini, E
    Salerno, RM
    Ferro, FM
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2006, 26 (01) : 45 - 49
  • [5] Mirtazapine Combination in Treatment-Resistant Major Depressive Disorder: A Retrospective Evaluation of Six Weeks
    Aydemir, Omer
    Deveci, Artuner
    Taskin, E. Oryal
    KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, 2009, 19 (04): : 347 - 352
  • [6] Clostridium butyricum MIYAIRI 588 as Adjunctive Therapy for Treatment-Resistant Major Depressive Disorder: A Prospective Open-Label Trial
    Miyaoka, Tsuyoshi
    Kanayama, Misako
    Wake, Rei
    Hashioka, Sadayuki
    Hayashida, Maiko
    Nagahama, Michiharu
    Okazaki, Shihoh
    Yamashita, Satoko
    Miura, Shoko
    Miki, Hiroyuki
    Matsuda, Hiroyuki
    Koike, Masahiro
    Izuhara, Muneto
    Araki, Tomoko
    Tsuchie, Keiko
    Azis, Ilhamuddin Abdul
    Arauchi, Ryosuke
    Abdullah, Rostia Arianna
    Oh-Nishi, Arata
    Horiguchi, Jun
    CLINICAL NEUROPHARMACOLOGY, 2018, 41 (05) : 151 - 155
  • [7] Mirtazapine in the treatment of panic disorder: an open-label trial
    Sarchiapone, M
    Amore, M
    De Risio, S
    Carli, V
    Faia, V
    Poterzio, F
    Balista, C
    Camardese, G
    Ferrari, G
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2003, 18 (01) : 35 - 38
  • [8] Pramipexole augmentation in treatment-resistant major depressive disorder
    Pae, Chi-Un
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2014, 14 (01) : 5 - 8
  • [9] Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: An open-label trial
    Fava, M
    Dunner, DL
    Greist, JH
    Preskorn, SH
    Trivedi, MH
    Zajecka, J
    Cohen, M
    JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (06) : 413 - 420
  • [10] An open-label trial of riluzole in patients with treatment-resistant major depression
    Zarate, CA
    Payne, JL
    Quiroz, J
    Sporn, J
    Denicoff, KK
    Luckenbaugh, D
    Charney, DS
    Manji, HK
    AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (01): : 171 - 174
12345